Thyroid cancer in children

被引:58
作者
Dinauer, Catherine
Francis, Gary L.
机构
[1] Virginia Commonwealth Univ, Coll Med, Dept Pediat, Div Endocrinol & Metab, Richmond, VA 23298 USA
[2] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA
关键词
D O I
10.1016/j.ecl.2007.04.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In 1996, the authors were asked to review the subject of thyroid cancer in children. Over the subsequent decade, much has been learned about the treatment and outcome of these uncommon tumors. We now recognize quantitative and perhaps qualitative differences in genetic mutations and growth factor expression patterns in childhood thyroid cancers compared with those of adults. We also know that thyroid cancers induce a robust immune response in children that might contribute to their longevity. Patients under 10 years of age probably represent a unique subset of children at particularly high risk for persistent or recurrent disease; the management of these patients is under evaluation. We remain limited in our knowledge of how to stratify children into low-and high-risk categories for appropriate long-term follow-up and in our knowledge of how to treat children who have detectable serum thyroglobulin but negative imaging studies. In this article, the authors update our understanding of thyroid cancers in children with special emphasis on how these data relate to the current guidelines for management of thyroid cancer developed by the American Thyroid Association Taskforce. The limited data regarding management of children who have detectable serum thyroglobulin but negative whole-body scans are also reviewed.
引用
收藏
页码:779 / +
页数:29
相关论文
共 190 条
[1]  
AHMED SR, 1984, NEW ENGL J MED, V311, P1576
[2]   Telomerase activity and its clinicopathological significance in gastric cancer [J].
Ahn, MJ ;
Noh, YH ;
Lee, YS ;
Lee, JH ;
Chung, TJ ;
Kim, IS ;
Choi, IY ;
Kim, SH ;
Lee, JS ;
Lee, KH .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (08) :1309-1313
[3]   Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer [J].
Antonelli, A ;
Miccoli, P ;
Fallahi, P ;
Grosso, M ;
Nesti, C ;
Spinelli, C ;
Ferrannini, E .
THYROID, 2003, 13 (05) :479-484
[4]   OUTCOME OF PREGNANCY FOLLOWING TREATMENT OF WELL-DIFFERENTIATED THYROID-CANCER WITH I-131 [J].
BALAN, KK ;
CRITCHLEY, M .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1992, 99 (12) :1021-1024
[5]  
Ball DW, 2000, THYROID CANCER, P365
[6]   Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: Effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation [J].
Barbaro, D ;
Boni, G ;
Meucci, G ;
Simi, U ;
Lapi, P ;
Orsini, P ;
Pasquini, C ;
Piazza, F ;
Caciagli, M ;
Mariani, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (09) :4110-4115
[7]   Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients [J].
Baudin, E ;
Do Cao, C ;
Cailleux, AF ;
Leboulleux, S ;
Travagli, JP ;
Schlumberger, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (03) :1107-1111
[8]  
BAUER RJ, 2004, PEDIAT ENDOCRINOLOGY
[9]  
Benua R.S., 1986, Frontiers in Thyroidology, VVolume 2, P1317
[10]   Thyroid-hormone therapy and thyroid cancer: a reassessment [J].
Biondi, B ;
Filetti, S ;
Schlumberger, M .
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2005, 1 (01) :32-40